{"paper_id":"fc46bc78-8303-407a-b473-1a4d1572e98e","body_text":"Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.\nConfirmation of menopause based on changes in follicle-stimulating hormone levels in patients who were administered dienogest\nAffiliation\nArticle Info\n1 Department of Obstetrics and Gynecology, Kanazawa Medical University, School of Medicine, Uchinada, Japan\nAbstract\nPurpose of investigation: The appropriate time for patients to discontinue dienogest (DNG) after long-term use has been a recent topic of debate. Therefore, this study evaluated the timing for discontinuation of DNG in climacteric patients suffering from endometriosis and adenomyosis. Materials and Methods: DNG was orally administered at 2 mg/day for more than 12 months. The serum estradiol (E2) and follicle-stimulating hormone (FSH) levels were measured every three to six months. DNG was discontinued when the hormone levels changed to those characteristic of menopause. Results: FSH levels in three patients increased to more than 25.8 mIU/mL during DNG administration. They were thus diagnosed as having entered menopause. There was no recurrence of pain in these patients at one year after discontinuation of DNG. Conclusion: An increase in serum FSH levels could help in confirming the diagnosis of menopause. In addition, DNG prevented the recurrence of endometriosis and adenomyosis.\nKeywords\n- Dienogest\n- Endometriosis\n- Adenomyosis\n- Estradiol\n- Follicle-stimulating hormone","source_license":"CC0","license_restricted":false}